Drugs / IMO-3100
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01622348 Comparator | May → Nov 2012 | psoriasis | Idera Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMO-3100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01622348 ↗ |
| Route | Subcutaneous | “IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection” NCT01622348 ↗ |